| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Research Communication |
1 From the Departments of Applied Chemistry and Microbiology (AMT and MM) and Animal Science (JMG), University of Helsinki; the Biomarker Laboratory, Department of Health and Functional Capacity, National Public Health Institute (AA and IS), Helsinki; the Department of Geriatrics, Uppsala University, Uppsala, Sweden (SB); and the Department of Animal Sciences, The Ohio State University, Wooster (DLP).
2 Supported by the National Dairy Council (United States), the Dairy Research and Development Corporation (Australia), and the Dairy Farmers of Canada. The high–oleic acid oil was provided by the Raisio Group, Raisio, Finland.
3 Reprints not available. Address correspondence to AM Turpeinen, University of Helsinki, Department of Applied Chemistry and Microbiology, PO Box 27, 00014 Helsinki, Finland.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
9-desaturase. There are indications that this conversion also occurs in humans. Objective: The aim of this controlled intervention was to study the conversion of VA to RA in humans after consumption of diets with increasing amounts of VA.
Design: Thirty healthy subjects consumed a baseline diet rich in oleic acid for 2 wk. The subjects were then divided into 3 groups (n = 10 per group) and provided a diet containing 1.5, 3.0, or 4.5 g VA/d for 9 d. All diets contained equal amounts of macronutrients and differed only in their fatty acid compositions. The fats were mixed into conventional foods, and nearly all food was provided during the study.
Results: The proportion of VA in serum total fatty acids increased 94%, 307%, and 620% above baseline with the 1.5-, 3.0-, and 4.5-g diets, respectively. This was associated with a linear increase in the proportion of RA. The conversion rate was 19% on average, with significant interindividual differences with all 3 intakes of VA. The urinary excretion of 8-iso-prostaglandin F2
increased in all groups (P < 0.001).
Conclusions: The results quantify the desaturation of VA to RA in humans. Conversion is likely to contribute significantly to the amount of RA available to the body, and dietary intakes of VA should thus be taken into account when predicting RA status.
Key Words: Vaccenic acid • rumenic acid • conjugated linoleic acid • trans fatty acids • endogenous synthesis • 9-desaturase • isoprostanes
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Ruminant fat is the main dietary source of CLA (2). Consumption of milk fat correlates with CLA concentrations in plasma (3), adipose tissue (4), and human milk (5). The daily intake of CLA in Western populations has been estimated to be 50–300 mg/d. The current intake, however, is lower than intakes that have had beneficial health effects in animal studies.
Vaccenic acid (11-trans-octadecenoic acid; VA) is a major trans fatty acid in milk fat, constituting 
1.7% (range: 0.4–4%) of the total fatty acid content (6). VA is also an intermediate in the biohydrogenation of polyunsaturated 18-carbon fatty acids to stearic acid in the rumen, and is the major precursor of CLA in milk fat (7). Desaturation of VA to rumenic acid (9-cis, 11-trans octadecenoic acid; RA) in tissues is catalyzed by 9-desaturase (EC 1.14.99.5) (8, 9). Bioconversion of VA to RA was shown and quantified in a recent study in mice (10). A study in humans noted that the CLA concentration in serum total lipids increases with consumption of a diet high in trans oleic acid (18:1), but the role of 9-desaturase was not confirmed in this context (11). Conversion of VA to RA in humans could substantially increase the amount of CLA available to the body.
Our aim was to confirm and quantify the conversion of VA to RA in humans. We conducted a controlled dietary intervention at 3 VA intakes in healthy humans. This design allowed us to estimate the extent to which dietary VA is converted to RA. Recent studies showed increases in the urinary excretion of lipid oxidation products after dietary CLA supplementation (12, 13). To examine whether endogenously formed CLA has a similar effect, we analyzed the urinary excretion of an indicator of arachidonic acid oxidation, 8-iso-prostaglandin F2 (8-iso-PGF2).
|
SUBJECTS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. The study protocol was approved by the ethics committees of the University of Helsinki and the National Public Health Institute, Helsinki. The subjects gave their written consent before entering the study.
|
3% of energy. High–oleic acid sunflower oil [85% oleic acid (18:1), Elsun 85 Extra; Raisio Group, Raisio, Finland] was used throughout the study in salad dressings, cooking, and baking. A commercial margarine (Kevyt Linja; Unilever Best Foods, Helsinki) was used as a bread spread. After the baseline period, the subjects were randomly allocated into 3 groups (n = 10 per group) and were provided a diet containing 1.5, 3.0, or 4.5 g VA/d during the experimental period. Sex was not balanced among treatments: n = 0 and 10, 5 and 5, and 3 and 7 men and women in the 1.5-g, 3.0-g, and 4.5-g treatment groups, respectively. The experimental fat was produced by Natural ASA (Hovdebygda, Norway). It was a mixture of fatty acids and contained (as a percentage of total fatty acids) 29.5% (VA), 32.1% 12-trans 18:1, 11.5% 11-cis 18:1, and 12.1% 12-cis 18:1. The fat was incorporated into desserts and bakery products.
All diets consisted of conventional solid foods and were designed to contain 30% of energy as fat, 15% as protein, and 55% as carbohydrates. A weekly rotating menu was used. On weekdays the subjects ate lunch at the Division of Nutrition, where they received the food to be consumed the rest of the day and the next morning; on Fridays they were given the food to be consumed over the weekend. Each participant’s food was weighed according to their energy level. Energy level was determined before the study began by using calculated surface area (14), age, and self-reported physical activity. Body weight in light clothing was recorded biweekly, and energy intake was adjusted to avoid weight changes.
In addition to the food supplied, which provided 90% of the daily energy intake, the subjects were allowed to choose a limited amount of fat- and cholesterol-free food items daily to provide the remaining 10% of daily energy intake. The participants kept diaries in which they recorded the foods they selected, the amount of free-choice foods eaten, any signs of illness, all medications used, and any deviation from their diets.
Duplicate portions of the diets were collected for 1 wk and homogenized. Before homogenization, 5 g butyl hydroxytoluene/kg (Merck, Germany) was added to prevent oxidation. The homogenized samples were freeze-dried and analyzed for total fat and nitrogen contents at the Agricultural Research Center of Finland, Jokioinen, and for fatty acid composition at the National Public Health Institute, Helsinki. The analyzed values were combined with the values calculated from the free-choice foods.
Blood and urine sampling
Fasting venous blood samples were collected with minimal stasis between 0730 and 1000 at the end of the baseline period (day 0) and on 4 mornings (days 2, 4, 6, and 9) during the experimental period. The blood samples for each subject were taken at the same time of the morning throughout the study.
Two 24-h urine samples were collected at the end of the baseline and experimental periods with the use of a Japanese aliquot cup (KK Izumi Seisakusyo Co, Ltd, Japan). The urine samples were divided into aliquots and stored at -70 °C. Urinary isoprostanes were analyzed from pooled individual samples from each period.
Serum total lipids and VLDLs
Serum total lipids were extracted and methylated as described by Folch et al (15) and Stoffel et al (16). Methylation was done with 1% H2SO4 in dry methanol. In our preliminary studies we found that 1% provides sufficient methylation but does not cause isomerization of CLA to a significant extent. The percentile distribution of methylated fatty acids was determined by gas chromatography (GC; model 6890 with the use of workstation software A.06.01; Hewlett-Packard, Palo Alto, CA) with a 60-m Supelco SP 2380 column (Supelco, Inc, Bellefonte, PA) and hydrogen as carrier gas. Fatty acid peaks from 14:0 to 22:6 were identified in a temperature-programmed run. Interassay variation was 0.5–2% for GC peaks > 1% and 1.5–5% for peaks < 1%. For RA, variation was 3%. The column does not separate 10-trans 18:1 and 11-trans 18:1 (VA) isomers. However, the baseline diet contained negligible amounts of both 10-trans and VA and there were no 10-trans isomers in the experimental fat. Thus, the 10–11-trans peak is referred to as VA.
VLDL was isolated from fresh serum samples by ultracentrifugation at a density of < 1.019 g/L (100 000 rpm, 3 h, and 5 °C) according to the method of Havel et al (17). A Beckman model L preparative centrifuge (Beckman Instruments, Inc, Palo Alto, CA) with a type TFT 45.6 rotor (Kontron Instruments, Zürich) was used, and the solution densities were adjusted with potassium bromide. The lipoprotein fraction was removed with the use of a standard tube-slicing technique (Spinco Tube Slicer; Beckman; 18) and stored at 4 °C. VLDL-triacylglycerol fatty acids were separated by thin-layer chromatography (19). Fatty acids were methylated and determined by GC as described for serum total fatty acids. VLDL triacylglycerols were further analyzed with Ag+ HPLC to separate 7-trans, 9-cis, and 9-cis, 11-trans CLA isomers (20).
Urinary isoprostanes
8-iso-PGF2, a major isoprostane and an indicator of nonenzymatic arachidonic acid oxidation, was analyzed from unextracted urine samples with the use of radioimmunoassay (21). In brief, an antibody raised in rabbits by immunization with 8-iso-PGF2 was used. The cross-reactivities of the antibody with 8-iso-15-keto-13,14-dihydro-PGF2; 8-iso-PGF2ß; PGF2; 15-keto-PGF2;15-keto-13,14-dihydro-PGF2; thromboxane B2; 11-ß-PGF2; 9-ß-PGF2
; and 8-iso-PGF3 were 1.7%, 9.8%, 1.1%, 0.01%, 0.01%, 0.1%, 0.03%, 1.8%, and 0.6%, respectively. The detection limit of the assay was 23 pmol/L. Intraassay mean values for the low and high spiked standards in the human plasma are 95.6% and 101%, respectively. Intraassay CVs of the low and high standards in the human plasma are 14.5% and 12.2%, respectively. The urinary concentrations of 8-iso-PGF2 were adjusted for creatinine values, which were measured with the use of a commercial kit (IL Test; Monarch Instrument, Amherst, NH).
Statistical analysis
Fatty acid data were analyzed as repeated measures according to the following model:
 | (1) |
The MIXED procedure of SAS (version 8.1; SAS Institute, Cary, NC) was used to estimate the parameters of the mixed model. The covariate value was the measurement from day 0 of the study. A first-order autoregressive structure was used to model the error variance–covariance matrix. The IML procedure of SAS was used to generate linear, quadratic, and cubic orthogonal polynomial coefficients for the unequally spaced days of measurements and their interactions with treatment. Two-factor repeated-measures analysis of variance was used to analyze the isoprostane data. Correlations were calculated by using Pearson’s correlation analysis. Differences with a P value < 0.05 were considered significant.
Estimation of the rate of bioconversion
The slope of linear regression of increases in RA versus VA plus RA in serum total lipids on day x - day 0 [ie, RA versus (RA + VA)] represents the rate of conversion and was used as an estimate of average conversion over the range of VA intakes studied.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
): the baseline diet was low in VA (< 0.2 g) and the intakes of VA in the 3 experimental diets were as planned. The CLA intake from the baseline diet was also low and remained unchanged throughout the study.
|
and for VA and RA in Figure 1. In all 3 groups, the proportion of VA increased until day 4, and the response was linear (P < 0.001). RA also increased and reached a plateau after day 2 in all groups, but an increase was again seen on day 9; the dose response was linear (P < 0.0001).
|
|
Use of the slope of the linear regression RA versus VA + RA as an estimate of conversion gave an average conversion rate of 19% (Figure 2). This approach is valid because the dietary supply of CLA was small and constant (Table 2
); therefore, any increase in plasma RA could occur only by desaturation of dietary VA. Significant interindividual differences were observed in the conversion rate: 2- to 3-fold differences in total increases in plasma RA were seen in all groups. In the 1.5-g group, one subject was a nonresponder (ie, no significant change in RA was seen, although serum VA increased). Four subjects in the 4.5-g group were identified as low responders (ie, those with an average increase in VA, but an increase in RA > 25% below the average) (Figure 2).
|
). Quadratic effects of sample day were seen for several fatty acids. However, none of the trends were large or influenced the data importantly. No changes were seen in the concentration of the 7-trans, 9-cis CLA isomer (data not shown), which coelutes with RA on GC. The 7-trans, 9-cis CLA isomer represented only a minimal proportion (5%) of the RA peak throughout the study.
The urinary excretion of 8-iso-PGF2 increased significantly from baseline (P < 0.001) in all 3 groups (0.294 to 0.468, 0.243 to 0.457, and 0.339 to 0.560 nmol/mmol creatinine in the 1.5-, 3.0-, and 4.5-g groups, respectively), representing 59%, 88%, and 65% increases, respectively. No significant differences between groups (P = 0.147) and no correlation between serum RA and urinary 8-iso-PGF2 was found.
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The existence of 9-desaturase, an enzyme that desaturates saturated fatty acids to monounsaturated fatty acids (eg, palmitic to palmitoleic acid and stearic acid to 18:1) was first identified in rats > 25 y ago (22) and thereafter in mice, bovines, and chickens (23). It was later shown that the same enzyme is also responsible for the conversion of VA to RA (8, 9). To quantify 9-desaturase activity and the conversion of VA to RA, pure VA was fed to mice in a recent study (10). Eleven percent of dietary VA was converted to RA, as assessed by carcass analysis. Of the VA absorbed and stored, 51% was converted. Also, in lactating dairy cows, 64% of the CLA in milk fat was estimated to be of endogenous origin (7).
A similar pathway for desaturation of VA was suggested to occur in humans, whereas evidence for this has been somewhat inconsistent. No conversion was detected in 2 subjects fed a single dose of deuterium-labeled VA (7–8 g as triacylglycerol) and followed for 48 h (24). However, a recent reanalysis of the data of one subject led the authors to conclude that VA was converted to RA (25). A controlled human intervention study showed a significant accumulation of CLA (from 0.32% to 0.43% of plasma fatty acids), despite an 87% reduction in CLA intake, in serum fatty acids of 40 healthy subjects who consumed a diet rich in VA (3 g/d) for 5 wk after consumption of a diet high in dairy fat (11). In a group consuming a high–stearic acid diet after the diet high in dairy fat, serum CLA decreased from 0.34% to 0.17%.
Consistent with the results of our preliminary study in 3 volunteers (data not shown), serum VA and RA reached a plateau after 2–4 d in the present study. However, we observed an increase in serum RA again on the last day (day 9) of the study in all groups. An increase in VLDL triacylglycerols was also seen, indicating that the increase was not due to enrichment of RA in serum pools with slower turnover rates, such as phospholipids or cholesterol esters. The reason for this increase in unknown, but we cannot exclude the possibility of a "weekend effect" because the last sample was taken on a Monday morning. Although the subjects were given instructions on when to eat the desserts and bakery products containing VA, eating habits during the weekend may have been slightly different from those adopted on weekdays.
Although slight changes in serum saturated fatty acids and in long-chain PUFAs were seen during the study, significant differences between the 3 groups were observed only in VA and RA. Because the proportion of 7-trans, 9-cis CLA separated from RA by Ag+ HPLC remained unchanged, it was concluded that appreciable amounts of 7-trans 18:1 were not present in the diet to be desaturated to 7-trans, 9-cis CLA and did not contribute to changes in the RA peak.
The conversion rate over the range of VA intakes studied was 19%. Interindividual differences were prominent, ranging from one nonresponder in the 1.5-g group to a conversion rate > 30% in another subject. The finding of 4 low responders in the 4.5-g group suggests that the enzyme became saturated in some individuals. However, because ruminant fat contains 2–3 times more VA than RA (26, 27), even low rates of conversion contribute significantly to body CLA status. The present data suggest that the total contribution of ruminant fat to body CLA status is likely to be on average 1.5 times the CLA content because of endogenous synthesis from VA.
The distribution of 9-desaturase activity in human tissues is unknown. Liver is the principal tissue for fatty acid synthesis in humans and presumably also has the highest 9-desaturase activity. It has been postulated that CLA might also be synthesized from linoleic acid through anaerobic microbial activity in the large bowel (28). However, a diet rich in linoleic acid (safflower oil) did not increase plasma CLA in humans, suggesting that it is unlikely that synthesis in the bowel would have a significant contribution to body CLA status (29).
Dietary factors may significantly affect desaturase activity. In animals, dietary PUFAs suppress 9-desaturase activity (30), whereas cholesterol (31), carbohydrates (32), and a fat-free diet (33) are known to increase the activity. In mice, increasing dietary PUFAs from 4% to 10% decreased the desaturation of VA to RA by 30% (10). In the present study, the baseline and experimental diets were designed to provide similar intakes of cholesterol, and the intake of PUFAs was limited to 3% of energy (7–8 g/d).
Early studies suggest that antioxidant activity could explain the anticarcinogenic (34, 35) and antiatherogenic (36) effects of CLA, but several, although not all (37), recent studies have shown the susceptibility of CLA to in vitro oxidation to be comparable with or higher than that of linoleic acid (38–41). The anticarcinogenic effects and cytotoxicity of CLA in cancer cell lines may be partly due to increased lipid oxidation (42, 43). Isoprostanes are formed in the body from PUFAs via nonenzymatic pathways, in contrast with eicosanoids, which are formed via enzymatic pathways. Isoprostanes are seen as in vivo indicators of lipid oxidation because increased synthesis was reported in a variety of clinical conditions associated with oxidative stress (44). Two recent studies in humans showed increased excretion of isoprostanes after CLA feeding (12, 13). Urinary 8-iso-PGF2 (a product of the nonenzymatic peroxidation of arachidonic acid) and 15-keto-dihydro-PGF2 (a product of the enzymatic peroxidation of arachidonic acid) both increased after daily CLA supplementation (4.2 g/d, containing equal amounts of the 9-cis, 11-trans and 10-trans, 12-cis CLA isomers) of healthy subjects for 3 mo (12). Enhancement in urinary isoprostanes was also seen in middle-aged men with abdominal obesity after only 1 mo of consuming mixed isomers of CLA (4.2 g/d) (13). Isoprostane concentrations returned to baseline 2 wk after the cessation of CLA intake. In agreement with the results of Basu et al (12, 13), we observed an increase in the urinary excretion of 8-iso-PGF2 in all groups with intake of mixed isomers of CLA, although not as pronounced as in the aforementioned studies. This suggests that the effects of exogenously (dietary) and endogenously formed CLA on isoprostane production are not different
The intake of CLA in Western populations is too low to provide the beneficial effects observed in animal studies. However, data from the present study warrant a reevaluation of the amount of CLA available to the body and indicate that the dietary intake of VA should also be taken into account when predicting CLA status. Conversion of VA to RA by 9-desaturase probably contributes significantly to CLA status.
|
ACKNOWLEDGMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-Linolenic acid in rapeseed oil partly compensates for the effect of fish oil restriction on plasma long chain n-3 fatty acids. Eur J Clin Nutr 1996;50:229–35.[Medline]
: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998;58:319–25.[Medline]
This article has been cited by other articles:
|
|
 |
|
  M. L. Nelson, J. R. Busboom, C. F. Ross, and J. V. O'Fallon Effects of supplemental fat on growth performance and quality of beef from steers fed corn finishing diets J Anim Sci, April 1, 2008; 86(4): 936 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Shingfield, S. Ahvenjarvi, V. Toivonen, A. Vanhatalo, and P. Huhtanen Transfer of Absorbed cis-9, trans-11 Conjugated Linoleic Acid into Milk Is Biologically More Efficient than Endogenous Synthesis from Absorbed Vaccenic Acid in Lactating Cows J. Nutr., May 1, 2007; 137(5): 1154 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Eckel, S. Borra, A. H. Lichtenstein, and S. Y. Yin-Piazza Understanding the Complexity of Trans Fatty Acid Reduction in the American Diet: American Heart Association Trans Fat Conference 2006: Report of the Trans Fat Conference Planning Group Circulation, April 24, 2007; 115(16): 2231 - 2246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Bu, J. Q. Wang, T. R. Dhiman, and S. J. Liu Effectiveness of Oils Rich in Linoleic and Linolenic Acids to Enhance Conjugated Linoleic Acid in Milk from Dairy Cows J Dairy Sci, February 1, 2007; 90(2): 998 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kuhnt, A. Wagner, J. Kraft, S. Basu, and G. Jahreis Dietary supplementation with 11trans- and 12trans-18:1 and oxidative stress in humans. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 981 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Mosley, M. K. McGuire, J. E. Williams, and M. A. McGuire Cis-9, Trans-11 Conjugated Linoleic Acid Is Synthesized from Vaccenic Acid in Lactating Women J. Nutr., September 1, 2006; 136(9): 2297 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Badinga and E. S. Greene Physiological Properties of Conjugated Linoleic Acid and Implications for Human Health Nutr Clin Pract, August 1, 2006; 21(4): 367 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Poirier, J. S. Shapiro, R. J. Kim, and M. A. Lazar Nutritional Supplementation With trans-10, cis-12-Conjugated Linoleic Acid Induces Inflammation of White Adipose Tissue Diabetes, June 1, 2006; 55(6): 1634 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kraft, L. Hanske, P. Mockel, S. Zimmermann, A. Hartl, J. K. G. Kramer, and G. Jahreis The Conversion Efficiency of trans-11 and trans-12 18:1 by {Delta}9-Desaturation Differs in Rats J. Nutr., May 1, 2006; 136(5): 1209 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tricon, G. C Burdge, E. L Jones, J. J Russell, S. El-Khazen, E. Moretti, W. L Hall, A. B Gerry, D. S Leake, R. F Grimble, et al. Effects of dairy products naturally enriched with cis-9,trans-11 conjugated linoleic acid on the blood lipid profile in healthy middle-aged men. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 744 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Raff, T. Tholstrup, K. Sejrsen, E. M. Straarup, and N. Wiinberg Diets Rich in Conjugated Linoleic Acid and Vaccenic Acid Have No Effect on Blood Pressure and Isobaric Arterial Elasticity in Healthy Young Men J. Nutr., April 1, 2006; 136(4): 992 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Mosley, B. Shafii{dagger}, P. J. Moate, and M. A. McGuire cis-9, trans-11 Conjugated Linoleic Acid Is Synthesized Directly from Vaccenic Acid in Lactating Dairy Cattle J. Nutr., March 1, 2006; 136(3): 570 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tholstrup, M. Raff, S. Basu, P. Nonboe, K. Sejrsen, and E. M Straarup Effects of butter high in ruminant trans and monounsaturated fatty acids on lipoproteins, incorporation of fatty acids into lipid classes, plasma C-reactive protein, oxidative stress, hemostatic variables, and insulin in healthy young men Am. J. Clinical Nutrition, February 1, 2006; 83(2): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Bell, J. M. Griinari, and J. J. Kennelly Effect of Safflower Oil, Flaxseed Oil, Monensin, and Vitamin E on Concentration of Conjugated Linoleic Acid in Bovine Milk Fat J Dairy Sci, February 1, 2006; 89(2): 733 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Allred, T. R. Dhiman, C. P. Brennand, R. C. Khanal, D. J. McMahon, and N. D. Luchini Milk and Cheese from Cows Fed Calcium Salts of Palm and Fish Oil Alone or in Combination with Soybean Products J Dairy Sci, January 1, 2006; 89(1): 234 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Desroches, P Y. Chouinard, I. Galibois, L. Corneau, J. Delisle, B. Lamarche, P. Couture, and N. Bergeron Lack of effect of dietary conjugated linoleic acids naturally incorporated into butter on the lipid profile and body composition of overweight and obese men Am. J. Clinical Nutrition, August 1, 2005; 82(2): 309 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Lock, C. A. M. Horne, D. E. Bauman, and A. M. Salter Butter Naturally Enriched in Conjugated Linoleic Acid and Vaccenic Acid Alters Tissue Fatty Acids and Improves the Plasma Lipoprotein Profile in Cholesterol-Fed Hamsters J. Nutr., August 1, 2005; 135(8): 1934 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Ritzenthaler, M. K. McGuire, M. A. McGuire, T. D. Shultz, A. E. Koepp, L. O. Luedecke, T. W. Hanson, N. Dasgupta, and B. P. Chew Consumption of Conjugated Linoleic Acid (CLA) from CLA-Enriched Cheese Does Not Alter Milk Fat or Immunity in Lactating Women J. Nutr., March 1, 2005; 135(3): 422 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Lynch, A. L. Lock, D. A. Dwyer, R. Noorbakhsh, D. M. Barbano, and D. E. Bauman Flavor and Stability of Pasteurized Milk with Elevated Levels of Conjugated Linoleic Acid and Vaccenic Acid J Dairy Sci, February 1, 2005; 88(2): 489 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Scholljegerdes, B. W. Hess, G. E. Moss, D. L. Hixon, and D. C. Rule Influence of supplemental cracked high-linoleate or high-oleate safflower seeds on site and extent of digestion in beef cattle J Anim Sci, December 1, 2004; 82(12): 3577 - 3588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Lock, B. A. Corl, D. M. Barbano, D. E. Bauman, and C. Ip The Anticarcinogenic Effect of trans-11 18:1 Is Dependent on Its Conversion to cis-9, trans-11 CLA by {Delta}9-Desaturase in Rats J. Nutr., October 1, 2004; 134(10): 2698 - 2704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Palmquist, N. St-Pierre, and K. E. McClure Tissue Fatty Acid Profiles Can Be Used to Quantify Endogenous Rumenic Acid Synthesis in Lambs J. Nutr., September 1, 2004; 134(9): 2407 - 2414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Riserus, B. Vessby, J. Arnlov, and S. Basu Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men Am. J. Clinical Nutrition, August 1, 2004; 80(2): 279 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Sauer, R. T. Dauchy, D. E. Blask, J. A. Krause, L. K. Davidson, E. M. Dauchy, K. J. Welham, and K. Coupland Conjugated Linoleic Acid Isomers and Trans Fatty Acids Inhibit Fatty Acid Transport in Hepatoma 7288CTC and Inguinal Fat Pads in Buffalo Rats J. Nutr., August 1, 2004; 134(8): 1989 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Kramer, C. Cruz-Hernandez, Z. Deng, J. Zhou, G. Jahreis, and M. E. Dugan Analysis of conjugated linoleic acid and trans 18:1 isomers in synthetic and animal products Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1137S - 1145S. [Abstract] [Full Text] [PDF]
|
|
; n = 10), or 4.5 g (
; n = 10) vaccenic acid daily.